Literature DB >> 35635216

SARS-CoV-2 variants and COVID-19 vaccines: Current challenges and future strategies.

Wenping Gong1, Seppo Parkkila2,3, Xueqiong Wu1, Ashok Aspatwar2.   

Abstract

The ongoing COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a global threat. Despite strict control measures implemented worldwide and immunization using novel vaccines, the pandemic continues to rage due to emergence of several variants of SARS-CoV-2 with increased transmission and immune escape. The rapid spread of variants of concern (VOC) in the recent past has created a massive challenge for the control of COVID-19 pandemic via the currently used vaccines. Vaccines that are safe and effective against the current and future variants of SARS-CoV-2 are essential in controlling the COVID-19 pandemic. Rapid production and massive rollout of next-generation vaccines against the variants are key steps to control the COVID-19 pandemic and to help us return to normality. Coordinated surveillance of SARS-CoV-2, rapid redesign of new vaccines and extensive vaccination are needed to counter the current SARS-CoV-2 variants and prevent the emergence of new variants. In this article, we review the latest information on the VOCs and variants of interest (VOIs) and present the information on the clinical trials that are underway on evaluating the effectiveness of COVID-19 vaccines on VOCs. We also discuss the current challenges posed by the VOCs in controlling the COVID-19 pandemic and future strategies to overcome the threat posed by the highly virulent and rapidly transmissible variants of SARS-CoV2.

Entities:  

Keywords:  Bacillus Calmette-Guerin (BCG); COVID-19; SARS-CoV-2; mutations; vaccines; variants

Year:  2022        PMID: 35635216     DOI: 10.1080/08830185.2022.2079642

Source DB:  PubMed          Journal:  Int Rev Immunol        ISSN: 0883-0185            Impact factor:   5.311


  1 in total

1.  The Natural Effect of BCG Vaccination on COVID-19: The Debate Continues.

Authors:  Wenping Gong; Huiru An; Jie Wang; Peng Cheng; Yong Qi
Journal:  Front Immunol       Date:  2022-07-08       Impact factor: 8.786

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.